HR positive/HER2 negative advanced or metastatic breast cancer

Clinical trials for HR positive/HER2 negative advanced or metastatic breast cancer explained in plain language.

Never miss a new study

Get alerted when new HR positive/HER2 negative advanced or metastatic breast cancer trials appear

Sign up with your email to follow new studies for HR positive/HER2 negative advanced or metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1 Not yet finished but already full! 2

New hope for Hard-to-Treat breast cancer: targeted combo enters final testing

Disease control Not yet recruiting

This Phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop the growth of advanced HR+/HER2- breast cancer in people whose cancer has returned or worsened after hormone therapy. The study includes 210 adults wit…

Matched conditions: HR POSITIVE/HER2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER

Phase 3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control

Last updated Jun 27, 2026 09:02 UTC

HR positive/HER2 negative advanced or metastatic breast cancer

Get alerted when new HR positive/HER2 negative advanced or metastatic breast cancer trials appear

New hope for Hard-to-Treat breast cancer: targeted combo enters final testing